| Market Cap | 12.51B | P/E | 6.64 | EPS this Y | -6.50% | Ern Qtrly Grth | -49.30% |
| Income | -56.1M | Forward P/E | 3.65 | EPS next Y | -0.40% | 50D Avg Chg | 6.00% |
| Sales | 15.36B | PEG | -1.64 | EPS past 5Y | -9.87% | 200D Avg Chg | - |
| Dividend | 5.00% | Price/Book | 0.60 | EPS next 5Y | -2.45% | 52W High Chg | -16.00% |
| Recommedations | 2.90 | Quick Ratio | 0.69 | Shares Outstanding | 1.19B | 52W Low Chg | 24.00% |
| Insider Own | 0.38% | ROA | 2.71% | Shares Float | 1.19B | Beta | 1.13 |
| Inst Own | 83.26% | ROE | -0.27% | Shares Shorted/Prior | 44.95M/36.39M | Price | 10.43 |
| Gross Margin | 43.47% | Profit Margin | -0.37% | Avg. Volume | 9,555,456 | Target Price | 15.57 |
| Oper. Margin | 12.03% | Earnings Date | Aug 5 | Volume | 8,361,564 | Change | 2.05% |
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
| Piper Sandler | Neutral | Mar 28, 24 |
| Piper Sandler | Neutral | Nov 22, 23 |
| B of A Securities | Underperform | Oct 23, 23 |
| Barclays | Underweight | Jun 23, 23 |
| Barclays | Equal-Weight | Apr 25, 23 |
| Barclays | Equal-Weight | Apr 24, 23 |
| Barclays | Overweight | Feb 28, 23 |
| BMO Capital | Market Perform | Feb 17, 23 |
| Barclays | Overweight | Feb 1, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Cuneo Andrew | See Remarks See Remarks | Jan 04 | Sell | 11.50 | 4,000 | 46,000 | 42,795 | 01/05/24 |
| Cuneo Andrew | See Remarks See Remarks | Dec 14 | Sell | 10.50 | 4,000 | 42,000 | 46,795 | 12/15/23 |
| Ni Xiangyang (Sean) | President, Greater C.. President, Greater China | Nov 23 | Sell | 9.37 | 14,937 | 139,960 | 64,658 | 11/24/23 |
| Ni Xiangyang (Sean) | President, Greater C.. President, Greater China | Nov 23 | Option | 0 | 33,179 | 79,595 | 11/24/23 | |
| Ni Xiangyang (Sean) | President, Greater C.. President, Greater China | Mar 02 | Sell | 11.13 | 6,241 | 69,462 | 46,416 | 03/06/23 |
| Ni Xiangyang (Sean) | President, Greater C.. President, Greater China | Mar 02 | Option | 0 | 15,600 | 49,564 | 03/06/23 | |
| Ni Xiangyang (Sean) | President, Greater C.. President, Greater China | Feb 27 | Sell | 11.22 | 5,250 | 58,905 | 37,057 | 03/01/23 |
| Ni Xiangyang (Sean) | President, Greater C.. President, Greater China | Feb 27 | Option | 0 | 13,142 | 42,307 | 03/01/23 | |
| Ni Xiangyang (Sean) | President, Greater C.. President, Greater China | Nov 23 | Option | 0 | 31,644 | 41,965 | 11/25/22 | |
| Ni Xiangyang (Sean) | President, Greater C.. President, Greater China | Nov 23 | Sell | 10.95 | 12,800 | 140,160 | 29,165 | 11/25/22 |
| van der Meer Mohr Pauline | Director Director | Aug 17 | Sell | 10.5839 | 9,440 | 99,912 | 20,543 | 08/19/22 |
| Taddese Menassie | See Remarks See Remarks | May 27 | Sell | 12.0737 | 8,813 | 106,406 | 05/27/22 | |
| READ IAN C | Director Director | Mar 21 | Option | 0.00 | 166 | 14,497 | 03/23/22 | |
| PARRISH MARK W | Director Director | Mar 21 | Option | 0.00 | 166 | 82,250 | 03/23/22 | |
| MARK RICHARD A | Director Director | Mar 21 | Option | 0.00 | 166 | 33,165 | 03/23/22 | |
| Lyons Dillon JoEllen | Director Director | Mar 21 | Option | 0.00 | 166 | 39,546 | 03/23/22 | |
| DIMICK NEIL F | Director Director | Mar 21 | Option | 0.00 | 166 | 75,200 | 03/23/22 | |
| KORMAN HARRY | Director Director | Mar 21 | Option | 0.00 | 166 | 50,638 | 03/23/22 | |
| KILTS JAMES M | Director Director | Mar 21 | Option | 0.00 | 166 | 79,402 | 03/23/22 | |
| HIGGINS MELINA E | Director Director | Mar 21 | Option | 0.00 | 166 | 63,068 | 03/23/22 | |
| CORNWELL W DON | Director Director | Mar 21 | Option | 0.00 | 166 | 22,197 | 03/23/22 | |
| CORNWELL W DON | Director Director | Mar 15 | Buy | 9.8968 | 2,700 | 26,721 | 22,031 | 03/15/22 |
| GOETTLER MICHAEL | Chief Executive Offi.. Chief Executive Officer | Mar 15 | Buy | 9.866 | 50,352 | 496,773 | 136,796 | 03/15/22 |
| COURY ROBERT J | Executive Chairman Executive Chairman | Mar 09 | Sell | 10.17 | 500,000 | 5,085,000 | 03/11/22 |